Literature DB >> 17968712

Targeting of stabilized plasmid lipid particles to hepatocytes in vivo by means of coupled lactoferrin.

Alida H Weeke-Klimp1, Martin Bartsch, Henriëtte W M Morselt, Ingrid Van Veen-Hof, Dirk K F Meijer, Gerrit L Scherphof, Jan A A M Kamps.   

Abstract

For non-viral gene delivery we prepared stabilized plasmid lipid particles (SPLPs), to which lactoferrin (LF) was coupled as a hepatocyte specific targeting ligand. LF-SPLPs and untargeted SPLPs labeled with [3H]cholesteryloleyl-ether were injected into rats. About 87% of the LF-SPLPs were eliminated from the blood within 5 min, while 80% of untargeted SPLPs were still circulating after 2 h. Fifty-two percent of the LF-SPLPs were taken up by hepatocytes, while non-parenchymal liver cells accounted for 16% of the uptake. Despite the efficient targeting of LF-SPLPs to hepatocytes and their capacity to transfect HepG2 and COS-7 cells in vitro, expression of a reporter gene was not detected in vivo. Overall, covalent coupling of LF to SPLPs leads to massive delivery in hepatocytes after systemic administration. However, these LF-SPLPs are not able to transfect these cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17968712     DOI: 10.1080/10611860701502889

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  3 in total

1.  Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.

Authors:  Minyan Wei; Xiucai Guo; Liuxiao Tu; Qi Zou; Qi Li; Chenyi Tang; Bao Chen; Yuehong Xu; Chuanbin Wu
Journal:  Int J Nanomedicine       Date:  2015-08-12

2.  In vitro and in vivo antitumor effects of lupeol-loaded galactosylated liposomes.

Authors:  Jun Zhang; Xixi Hu; Guohua Zheng; Hui Yao; Huali Liang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 3.  Potential Use of Biological Proteins for Liver Failure Therapy.

Authors:  Kazuaki Taguchi; Keishi Yamasaki; Hakaru Seo; Masaki Otagiri
Journal:  Pharmaceutics       Date:  2015-08-31       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.